BeiGene Ltd ( (HK:6160) ) has shared an update.
BeiGene, Ltd. has issued an overseas regulatory announcement regarding a pre-effective amendment to Form F-6, which was filed with the U.S. Securities and Exchange Commission. This filing pertains to the registration of American Depositary Shares (ADS) for BeOne Medicines Ltd., highlighting BeiGene’s ongoing regulatory activities and its strategic positioning in the global market.
More about BeiGene Ltd
BeiGene, Ltd. is a biotechnology company that focuses on developing and commercializing innovative molecularly targeted and immuno-oncology drug candidates for the treatment of cancer. The company operates globally with a significant presence in the Asian and North American markets.
YTD Price Performance: 44.69%
Average Trading Volume: 5,622,390
Technical Sentiment Signal: Sell
Current Market Cap: HK$235.3B
Learn more about 6160 stock on TipRanks’ Stock Analysis page.